Drugs / EEDVSMit
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02687386 | Feb 2016 → Dec 2021 | cancer, central nervous system neoplasm | Dr David Ziegler | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EEDVSMit | “This is an open-label, sequential dose exploration study of single agent EEDVSMit administered by intravenous (IV) infusion twice weekly, followed by weekly maintenance dosing,...” NCT02687386 ↗1“OBJECTIVE: To assess the safety and tolerability of EGFR-Erbitux receptor EnGeneIC Dream Vector with mitoxantrone (EEDVsMit) in children with recurrent / refractory solid or...” PMID 38546944 ↗ Mar 2024 |
| Known as | EGFR-Erbitux receptor EnGeneIC Dream Vector with mitoxantrone | “OBJECTIVE: To assess the safety and tolerability of EGFR-Erbitux receptor EnGeneIC Dream Vector with mitoxantrone (EEDVsMit) in children with recurrent / refractory solid or...” PMID 38546944 ↗ Mar 2024 |
| Known as | EGFR-ErbituxEDVsMIT | “A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor.” PMID 38546944 ↗ Mar 2024 |
| Action | Deplete | “Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.” NCT02687386 ↗ |
| Modality | Other / unclassified | “The EnGeneIC Dream Vector (EDV) is a novel nanocell designed to deliver cytotoxic medication directly to the tumour.” PMID 38546944 ↗ Mar 2024 |
| Route | Intravenous | “single agent EEDVSMit administered by intravenous (IV) infusion twice weekly” NCT02687386 ↗ |
| Target | EGFR | “The epidermal growth factor receptor is expressed in several CNS and solid tumours and is the target for bispecific antibodies attached to the EDV.” PMID 38546944 ↗ Mar 2024 |